Cancer has published a paper about rotation to methadone in the outpatient setting for cancer pain. It's a notable paper because very little has been published about this practice (although I think it's widespread in the hospice and palliative care world) - most of the published reports (mostly case series/retrospective chart reviews) have been in inpatients, where close monitoring for safety (and efficacy) can occur. So, while people are doing it, there hasn't been much support in the research literature about, at the very least, the safety of this practice.
This study is a retrospective chart review of a single center's (MD Anderson) experience with this. The paper includes data about patients initiated on methadone (as the first strong opioid), but I'll focus on the rotation data here. The patients (N=89, mean age 58, median baseline oral morphine equivalent daily dose [MEDD] of 100 mg) were rotated to methadone as outpatients, and had median first follow up at 13 days, and second at 37 days. The rotation protocol is not specified in great detail (and they imply there is not a set protocol for this group - instead more of general parameters that are adjusted based on the physician's discretion). It seems generally a start/stop strategy (discontinue prior opioids, initiate methadone the same day) was used. Morphine to methadone ratios that were used were 5:1 for MEDD less than 90 mg/day; 8:1 for 91 to 300 mg/day; and 12:1 for MEDDs over 301 mg/day. What is done with the breakthrough medication is not specified. It's important to note that the range of baseline MEDD was 60-185 mg: these patients were being rotated to methadone at moderate morphine doses, not once patients were taking many hundreds (or thousands) of mg a day.
This was a retrospective chart review, of one group's real-life practice, and the criteria for evaluating the reason for rotation to methadone, as well as its success, were based on the research team's best efforts at abstracting from chart data. They tried to identify why patients were rotated (inadequate analgesia, non-methadone opioid side effects, or both) and then if the rotation was successful upon follow-up (pain improvement greater than 30% or 2/10 on a 11-point rating scale, reduction in the side effects which prompted the rotation, etc.). If these targets were clearly met the rotation was labeled as success; if the methadone was discontinued, the patient was admitted to the hospital for pain or methadone related side effects, or if the patient was lost to follow-up, the rotation was labeled a failure. Everything else was labeled a 'partial success' (indicating, at least, the patient tolerated the rotation adequately to continue methadone and not be admitted with side effects).
The major data on success were positive: 47% had a 'complete success', 38% a partial success, and 15% a 'failure.'*** The best rates of success were for patients rotated only for side effects, although this was only 5 patients. Median methadone doses were 15 mg/day at the first follow up and 18 mg/day at the 2nd. They did plot baseline MEDD with stable methadone dose, and confirmed the previous findings that baseline MEDD is associated with MEDD:methadone ratio (e.g. the higher the baseline MEDD, the higher the ratio, and the lower relative amount of methadone patients need). And in fact the median MEDD:methadone ratio they identified after patients were stable were 5:1 and 8:1 for MEDDs less than 90, and greater than 90 mg daily, respectively (which is of course their conversion ratio, suggesting that these are in fact reasonable ratios for patients with MEDDs less than 200 mg).
Most interesting is that they calculated MEDD:methadone ratios for patients who were rotated for pain vs. those rotated for side effects (with or without pain). In the 'side effect' patients the MEDD:methadone ratio was 9:1, and 6:1 for the 'pain' patients (ie the 'side effect' patients needed less methadone, relative to their baseline opioid dose, than the 'pain' patients).
In discussing the failures, they indicate these were due to non-efficacy, and don't discuss any toxicities.
All of this is good, and represents some of the first data (with a decent N for a study of this type) supporting the safety of outpatient methadone rotations for pain. I doubt a prospective study (even just a natural history one, with modest outcomes of safety at one month) is coming anytime soon. It's confirmatory of the broad trend in previously published chart reviews that methadone rotations are usually (for over 3/4 patients) helpful, although rigorously controlling for the reason for methadone rotation has never occurred and all the data we have is essentially descriptive and based on real-life clinician practice (which has both benefits and drawbacks in interpreting this).
The major caveat here is that this is for patients on moderate MEDDs - less than 200 mg a day. One cannot conclude from this that the practice is safe/advisable for patients on significantly higher doses (ie in the 500 mg and up range). Which raises the question of whether we should routinely be rotating patients to methadone once they're on, say, MEDDs of 100 mg or more, and who have uncontrolled pain or side effects. This research suggests only, of course, that the rotation to methadone in this setting can be successful, not that the patient was better off for it (as opposed to continuing up-titration of the prior opioid assuming the rotation wasn't for side effects, or rotating to a different opioid such as fentanyl). Trying to answer this in a trial would be difficult, but not impossible, and you do kind of wish there was a methadone lobby to support such research. My guess is that there's a wide variation of practice out there, and I'd be curious as to what others do - when, why you switch to methadone - a simple mg cut off (ie propose it to a patient once they're at a certain MEDD regardless of how they're doing) or later? I tend to do it later, but am not convinced that is best: we have no data either way.
(***Addendum Jan 29, 2010: I had originally put in incorrect numbers for the % of complete or partial successes for the rotation; a commenter pointed this out and I've changed the numbers here for posterity. See the comments.)
Thursday, January 28, 2010
Outpatient rotations to methadone
Subscribe to:
Post Comments (Atom)





9 comments:
It looks like the percentages for rotations are actually 47% for complete success, 38% for partial success, and 15% for failure. (At least from the author manuscript at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811764/?tool=pubmed )
I tend not to begin methadone until a pt is already on several hundred mg of another med. I often will add methadone in at a low dose as an adjunct to another opiate, though--seems to spare some of the escalation of dosing that pts can get into with the other meds.
Once I have a pt on methadone as an adjunct, if the pt continues to need more opiate, I tend to increase the methadone rather than the original opiate. Once the pt is tolerant to a dose of methadone that approximates their other opiate, I eventually convert the lesser opiate (such as extended release morphine or oxycodone) over into methadone. That helps to simplify med regimen.
I have also converted a couple pts being decertified from hospice to palliative care from oxycodone ER to methadone. This was primarily because of insurance coverage (Medicaid)--that was the only way the pts would be able to afford/get any pain meds
We routinely use Methadone in our hospice for pts with bone pain. Follow up is much more extensive than mentioned in this blog, with home visits at 1, 3, 5, and 7 days to assess for toxicity. No titration up is started until the end of the first week, so breakthrough meds are certainly required. It's like a miracle for a lot of our folk.
Another recent paper from this group at M.D. Anderson Cancer Center addressed alleged cardiotoxicity of methadone and found minimal QTc-prolongation or torsade risk in patients with cancer. We discuss details in our weblog at http://Updates.Pain-Topics.org (posting on 1/27/10).
Along with the discussion above, outpatient rotation to methadone, and possible concerns about over-medication or overdose presents a wonderful opportunity to also prescribe the antidote – intranasal naloxone – along with instructions for at-home use by relatives and caregivers. Prefilled naloxone syringes and atomizer tips are available; albeit, not from the local pharmacy. We also discussed this at the Updates weblog (posting on 12/4/09).
Hope this helps…. SBL
(((Ok I just wrote a long comment about this which Blogger ate, and I'm not going to repeat it all again right now...anyway Bruce you are right, thanks: I amended the original blog post, with a footnote, for posterity. I had merged data from two rows from Table 2 in the original post: it's fixed now. Thankfully it doesn't change the overall results.)))
I agree with Dr. Pam's assessment of putting off methadone for those patients requiring unusually high doses of another narcotic. That doesn't happen too often.
Despite reassurance about QT-prolongation risk from a well-seasoned hospice physician friend, I'm anxious enough to keep methadone as a 2nd or 3rd option, or a "special situation" medication.
I tend to use methadone as more of a 1st line drug since it has many advantages that other opioids do not (cheap, long half life, NMDA antagonist activity -> good for neuropathic pain, available in liquid form). I get baseline ECGs even though I am not too concerned about the risk of QT prolongation, since most patients in the hospice/palliative care setting have such a high mortality risk from many other causes, it makes the concern for QT prolongation seem trite.
How many of you keep your hospice patients on continuous cardiac monitoring?
I also use it as a first line drug for many of my patients. I especially like to use it for the end stage bedbound dementia patient with muscle stiffness and contractures. I find great success in this population because they usually don't have pain until they have a diaper change or are repositioned. Breakthrough medication makes no sense in this situation because by the time it kicks in, the body manipulation is done. Also, usually in nursing home they don't remember to premedicate. I like methaonde because with Methadone Intensol (10mg/ml) I can start at 1mg po/sl q8 or q12 hours routine and titrate based on response. This has worked well in this population in addition to all my cancer patients that have not done well with other opioids. Just as Rhonda Palmer said, I've also had great success stories with methadone.
Thanks all for your comments - clearly wide variations in how people use it. To Anon re: QT monitoring I tend to get a baseline EKG as well to make sure the patient doesn't have a grossly long QTc at baseline but I don't otherwise follow or repeat it for patients with short prognoses. The article that Stew Leavitt points to is a good one and has been confirmatory that the absolute risk of QTc prolongation and arrhythmia is low.
Post a Comment